ClinicalTrials.gg
WithdrawnNCT04705844COMBAATUpdated Mar 3, 2022

Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)

A Phase 3 interventional study of Adalimumab and Placebo in Mild to Moderate COVID-19, sponsored by Resilience Government Services, Inc.. Withdrawn. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-03-03.

Sponsored by Resilience Government Services, Inc. (part of National Resilience, Inc.) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
study withdrawn prior to screening subjects

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

Clinical study of Humira (adalimumab) or placebo in subjects with mild-moderate COVID-19

02

Conditions studied

  • Mild to Moderate COVID-19

Browse trials for

03

In context

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Lead sponsor

Resilience Government Services, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.

Unclear whether first submitted before or after Resilience Government Services, Inc. became part of National Resilience, Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject (or their legally authorized representative) is willing and able to provide written prior to performing study procedures.
  • Understands and agrees to comply with planned study procedures.
  • Male or non-pregnant female adult ≥60 and ≤ 80years of age OR male or non-pregnant female adult ≥40 and ≤80 years, with one or more of the following risk factors (asthma, diabetes, hypertension, obesity [ >30], cardiovascular disease).
  • Has a laboratory-confirmed SARS-CoV-2 infection as determined by FDA-approved rapid diagnostic (e.g., polymerase chain reaction [PCR]) assay within the preceding 7 days (168 hours).
  • Has at least 2 COVID-19 related symptoms on the 14-question COVID-19 questionnaire.
  • Has peripheral capillary oxygen saturation (SpO2) >93% by pulse oximetry.
  • C-reactive protein (CRP) >50 mg/L or lymphopenia (\<1.5×109/L) or neutrophilia (>7.5×109/L).
  • Agrees to the collection of blood and urine samples, nasal swabs , and non-invasive oxygen monitoring (via pulse oximeter) per protocol.
  • Willing to receive 4 injections at separate sites on the thigh or abdomen.
  • Women of must agree to either abstinence or use of at least one primary form of (not including hormonal contraception) from the time of screening through Day 29 following randomization.
  • Agrees to not participate in any other clinical trial (both pharmacologic and other types of interventions) through Day 29 following randomization

Exclusion criteria

Exclusion Criteria:

  • Received or contemplating any COVID-19 vaccine or participated in a COVID-19 vaccine trial.
  • Subject is considered to be in their last few weeks of life prior to this acute illness.
  • History of pulmonary alveolar proteinosis.
  • History of hematopoietic stem cell transplant or solid organ transplant.
  • Previous and lymphoproliferative disorders (within the last 5 years) with the exception of stable prostate cancer and basal cell carcinoma.
  • on long-term oxygen therapy - subjects with known to be \<50% will also be excluded.
  • Demyelinating disease.
  • Known history of , , or untreated infection
  • Severe hepatic impairment or known cirrhosis - score B or higher.
  • Acute kidney injury Stage 3
  • Tuberculosis or other severe infections such as (non-COVID-19) sepsis, abscesses, fungal superinfection and opportunistic infections requiring treatment.
  • Positive Quantiferon Gold test at screening
  • Moderate or severe heart failure ( Class III/IV).
  • Treatment with monoclonal antibodies targeting cytokines (e.g., TNF inhibitors [adalimumab, infliximab, etanercept, golimumab, certolizumab]; anti-IL-1 [e.g., anakinra, canakinumab]; anti-IL-6 or anti-IL-6r [e.g., tocilizumab, sarilumab, sitlukimab]; or T-cells [e.g., abatacept]) in past 90 days (5 half-lives of the drug), or contemplating treatment with any of these agents during the trial period.
  • Treatment with monoclonal antibodies targeting B-cells (e.g., rituximab, and including any targeting multiple cell lines including B-cells) in the 3 months prior to screening.
  • Received GM-CSF agents (e.g., sargramostim) within 2 months prior to screening.
  • Treatment with other in the 4 weeks prior to screening and in the judgment of the Investigator, the risk of immunosuppression with adalimumab is larger than the risk of COVID-19.
  • Treatment with small molecule tyrosine kinase inhibitors (e.g., baricitinib, ibrutinib, acalabrutinib, imatinib, gefitinib), in the 4 weeks prior to screening.
  • Received or contemplating receipt of any or any vaccine in the 4 weeks prior to screening.
  • Current participation or previous participation in any other clinical trial within 30 days prior to randomization.
  • Subjects with known to adalimumab or of adalimumab as stated in the label.
  • Pregnant female
  • Lactating female
  • Women of who do not agree to either abstinence or use of at least one primary form of (not including hormonal contraception) from the time of screening through Day 29 following randomization.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Adalimumab

    single dose of adalimumab(160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen

    Drug: Adalimumab

  • Placebo comparator
    Placebo

    single dose of placebo (administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen

    Drug: Placebo

Interventions

  • adalimumab (160 mg administered as 4×40 mg subcutaneous \[SC\] injections at separate sites on the thigh or abdomen)

    Also known as: Humira

  • DrugPlacebo

    placebo (4 SC injections of equal volume administered at separate sites on the thigh or abdomen)

06

What researchers measure

Primary outcomes

  1. Establish whether treatment with adalimumab is associated with a lower rate of progression to severe disease as defined by severe illness or critical illness, or death in outpatient subjects with COVID-19

    Proportion of subjects with the following outcomes attributed to COVID-19 from time of first dose through Day 28 following randomization: * Death * Alive and hospitalized or requiring supplemental oxygen for ≥1 hour * Alive and not hospitalized or requiring supplemental oxygen for ≥1 hour

    Time frame: 28 Days

  2. Assess the safety of adalimumab in subjects with COVID-19

    Incidence of Grade 3 and Grade 4 clinical adverse events (AEs) from first dose through Day 28 following randomization

    Time frame: 28 Days

Secondary outcomes

  1. Assess the impact of treatment with adalimumab on clinical course of COVID-19 infection

    Clinical status by 9-point WHO COVID 19 ordinal scale from first dose through Day 120 following randomization * Incidence of venous thromboembolism, CVA, myocardial infarction, and acute kidney injury C from first dose through Day 120 following randomization * Time to resolution of symptoms using 14 point COVID-19 Symptom Score from first dose through Day 120 following randomization * COVID-19 Clinical Assessment from first dose through Day 120 following randomization

    Time frame: 120 Days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2021; primary completion for Sep 2022, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2021
First posted
Jan 12, 2021
StartEst.
Sep 2021
Primary completionEst.
Sep 2022
CompletionEst.
Sep 2022
Last update
Mar 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04705844
Collaborators
Pharm-Olam, LLC, Chemical, Biological, Radiological, and Nuclear Medical
Responsible party
Sponsor
First posted
Jan 12, 2021
Start date
Sep 2021 (estimated)
Primary completion
Sep 2022 (estimated)
Completion
Sep 2022 (estimated)
Last update
Mar 3, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion